Waltz Health and Fresenius Kabi have teamed up to provide employers, payers, and pharmacy benefit managers direct access to three competitively priced biosimilars for immunology and inflammatory diseases. The biosimilars include adalimumab-aacf (Humira biosimilar), Otulfi (Stelara biosimilar), and Tyenne (Actemra biosimilar), offered through a transparent pricing model to reduce costs and improve patient access. This partnership expands Waltz Health's Direct-to-Payer program, bypassing traditional rebate and wholesaler channels to offer predictable pricing and direct delivery through specialty pharmacies. The collaboration aims to lower specialty drug costs while maintaining high-quality treatment options for autoimmune and inflammatory conditions.
The Waltz Health and Fresenius Kabi partnership on biosimilars provides context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Sep 29, 2026 19:14 WIB: out of 100 priced US health-sector stocks, 50 rose and 41 fell. Among notable movers, TXG gained 1.39% with a typical hold time of 92 days and a nearly balanced Pluang order activity (49% Sell / 51% Buy), contrasting with PHG and WGS which declined by 1.47% and 1.37% respectively, with WGS showing 100% buy order activity despite its price drop.
Netflix shares rose 1.5% after Deutsche Bank upgraded the stock from Hold to Buy, citing recent price declines as a buying opportunity and stronger international trends. However, other analysts remain cautious, with Wells Fargo downgrading Netflix to...
Cytokinetics' CEO Robert I. Blum and other executives have recently sold large amounts of company stock, with Blum selling nearly 105,000 shares in total, including a major block under a pre-arranged trading plan. This insider selling occurs while th...
Carnival Corporation reported strong quarterly results with earnings per share of $1.43 and net income of $1.92 billion, surpassing analyst expectations. The company achieved record revenue of $8.44 billion, driven by growing consumer interest in cru...
FactSet is set to report strong Q3 earnings with an expected EPS of $4.35 and revenue around $629.83 million, reflecting a 5.3% increase from last year. The company benefits from high demand for AI-related products, expanded client base, and effectiv...
Jefferies Financial Group reported robust Q3 results with earnings per share of $1.09, beating analyst estimates and last year's $1.05. Revenue rose to $2.22 billion, driven by record banking revenue, surpassing expectations. Net earnings increased t...
